Enhanced circulation effector composition and method
First Claim
Patent Images
1. A liposome composition, comprisingliposomes, each having an outer layer of hydrophilic chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to a first binding member or a second binding member is effective to inhibit binding between said first and second binding members.
0 Assignments
0 Petitions
Accused Products
Abstract
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
17 Citations
48 Claims
-
1. A liposome composition, comprising
liposomes, each having an outer layer of hydrophilic chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to a first binding member or a second binding member is effective to inhibit binding between said first and second binding members.
-
7. A liposome composition for use in treating a condition mediated by binding of one binding member to a second binding member, comprising
liposomes, each having an outer layer of hydrophilic polymer chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
-
13. A liposome composition for use in treating a condition mediated by binding of one binding member, which is present in the bloodstream, to a second binding member, comprising
liposomes, each having an outer layer of hydrophilic polymer chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
- 14. The composition of clam 13 wherein the effector molecule is selected from the group consisting of Fab antibody fragments, cytokines, cellular growth factors, peptide hormones, monosaccharides, polysaccharides, IL-1 inhibitors, ELAM-1 binding inhibitors, and limulus antilipopolysaccharide factor (LALF).
-
19. A liposome composition for use in treating a condition mediated by binding of a first binding member, which is a pathogen or cell in the bloodstream, to a second binding member comprising
liposomes, each having an outer layer of hydrophilic polymer chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
-
25. A liposome composition for use in treating a condition mediated by binding of a first binding member to a second binding member, which is a target cell, comprising
liposomes, each having an outer layer of hydrophilic polymer chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
-
31. A liposome composition for use in treating a condition mediated by binding of a first binding member, which is a pathogen, to a second binding member, which is a target cell, comprising
liposomes, each having an outer layer of hydrophilic polymer chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
-
37. A liposome composition for use in treating a condition mediated by binding of a first binding member, which is a cell in the bloodstream, to a second binding member, which is a target cell, comprising
liposomes, each having an outer layer of hydrophilic polymer chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
-
43. A liposome composition for use in treating a condition mediated by binding of a first binding member, which is a pathogen or a cell in the bloodstream, to a second binding member, which is a target cell, comprising
liposomes, each having an outer layer of hydrophilic polymer chains, and an effector molecule attached to the distal ends of said chains wherein binding of the liposomes to one of said first or second binding members is effective to inhibit binding between said first and second binding members.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeALZA Corporation (Johnson & Johnson)
-
Original AssigneeALZA Corporation (Johnson & Johnson)
-
InventorsMartin, Francis J., Woodle, Martin C., Zalipsky, Samuel, Barenholz, Yechezkel, Bercovier, Herve
-
Primary Examiner(s)HUFF, SHEELA JITENDRA
-
Application NumberUS09/877,978Publication NumberTime in Patent Office753 DaysField of Search424/450, 424/85.8, 424/85.2, 424/85.4, 424/812, 530/319, 530/391.1, 530/350, 530/331-324US Class Current424/450CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/00 Medicinal preparations cont...A61K 38/12 Cyclic peptides , e.g. baci...A61K 38/1774 Immunoglobulin superfamily ...A61K 47/61 the organic macromolecular ...A61K 47/62 the modifying agent being a...A61K 47/6911 the form being a liposomeA61K 9/0019 Injectable compositions; In...A61K 9/1271 Non-conventional liposomes,...Y10S 424/812 Liposome comprising an anti...
